TC-002 Ophthalmic Solution
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for TC-002 Ophthalmic Solution, covering 2022-05-25 to 2022-05-25. Get the full timeline:
Most recent: Clinical Trial Update: Prospective, Double-masked, Randomized, Multi-center, Active-controlled, Parallel-group, 3-month Study Assessing the Safety & Ocular Hypotensive Efficacy of TC-002 Ophthalmic Solution Compared to Latanoprost Ophthalmic Solution 0.005% in Subjects With Elevated Intraocular Pressure [Phase 3]